Epithelial Ovarian Cancer Market

Market Overview:

The 7 major epithelial ovarian cancer markets reached a value of US$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 14.3 Billion by 2034, exhibiting a growth rate (CAGR) of 18.2% during 2024-2034.

The epithelial ovarian cancer market has been comprehensively analyzed in IMARC's new report titled "Epithelial Ovarian Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Epithelial ovarian cancer, also referred to as ovarian carcinoma, is a type of cancer that originates from the epithelial cells that line the outer surface of the ovaries. It often presents with nonspecific symptoms, which can make early disease detection a bit challenging. Some of the common indications associated with the ailment include abdominal bloating or discomfort, pelvic pain or pressure, changes in bowel or bladder habits, feeling full quickly while eating, unexplained weight loss, fatigue, changes in menstrual cycles, etc. Diagnosing epithelial ovarian cancer typically involves a combination of medical history assessment, physical examination, imaging tests, and tissue sampling. The process begins with a thorough evaluation of the patient's symptoms, medical history, and risk factors. A pelvic examination may be performed to check the condition of the ovaries. Numerous imaging procedures, such as transvaginal ultrasound, CT scan, MRI, etc., are used to visualize the ovaries and assess the extent of the disease. A biopsy is usually conducted to confirm the diagnosis, which helps to determine the type of ovarian cancer, its grade, and its stage. Additionally, genetic testing may be recommended to identify inherited gene mutations that could influence treatment decisions and guide genetic counseling.

The increasing cases of inherited gene mutations, particularly in the BRCA1 and BRCA2 genes, that disrupt the DNA repair process and lead to an accumulation of genetic errors, are primarily driving the epithelial ovarian cancer market. Besides this, the rising prevalence of several associated risk factors, such as long-term use of estrogen-only hormone replacement therapy, endometriosis, family history, obesity, etc., is creating a positive outlook for the market. Furthermore, the escalating usage of hormone therapy, which involves the use of medications that either block the production of hormones or interfere with their action, thereby slowing down the development of tumor, is also bolstering the market growth. Apart from this, the emerging popularity of intraperitoneal chemotherapy, since it delivers the chemotherapy drugs directly into the abdominal cavity and allows for higher drug concentrations in the area where ovarian cancer is most likely to spread, is acting as another significant growth-inducing factor. Moreover, the ongoing advancements in surgical techniques, including the introduction of precision-guided surgery and sentinel lymph node mapping, which aim to improve the extent of tumor removal while preserving healthy tissue and achieving optimal debulking, are expected to drive the epithelial ovarian cancer market in the coming years.    

IMARC Group's new report provides an exhaustive analysis of the epithelial ovarian cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for epithelial ovarian cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the epithelial ovarian cancer market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the epithelial ovarian cancer market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the epithelial ovarian cancer market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current epithelial ovarian cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the epithelial ovarian cancer market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the epithelial ovarian cancer market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the epithelial ovarian cancer market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of epithelial ovarian cancer across the seven major markets?
• What is the number of prevalent cases (2018-2034) of epithelial ovarian cancer by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of epithelial ovarian cancer by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with epithelial ovarian cancer across the seven major markets?
• What is the size of the epithelial ovarian cancer patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of epithelial ovarian cancer?
• What will be the growth rate of patients across the seven major markets?
   

Epithelial Ovarian Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for epithelial ovarian cancer drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the epithelial ovarian cancer market?
• What are the key regulatory events related to the epithelial ovarian cancer market?
• What is the structure of clinical trial landscape by status related to the epithelial ovarian cancer market?
• What is the structure of clinical trial landscape by phase related to the epithelial ovarian cancer market?
• What is the structure of clinical trial landscape by route of administration related to the epithelial ovarian cancer market?